Daxor corporation reports a 20.64 percent increase in diagnostic test kits revenue from prior year period in form n-csr filing for the six months ended june 30, 2023

Net assets increases to $30.4 million from $29.0 million oak ridge, tn, aug. 28, 2023 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, announces today it filed form n-csr disclosing its schedule of portfolio holdings for the six-months ended june 30, 2023. the unaudited financials reported included an increase in revenue of 20.64 percent in the company's diagnostic test kits compared to the same period from 2022 represents strong strides in the commercialization of its bva-100® blood volume analyzer through a combination of the purchase and leasing of capital equipment, the launch of daxor's ezbva lab service, and the opening of eight new commercial and academic accounts during the past six- months.
DXR Ratings Summary
DXR Quant Ranking